The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final analysis of a phase II, open label, randomized study of osimertinib versus osimertinib plus carboplatin/pemetrexed for patients with locally advanced or metastatic non-small cell lung cancer whose disease has progressed with previous EGFR-TKI and whose tumours harbour a T790M mutation (LOGIK1604/NEJ032A).
 
Kentaro Tanaka
Honoraria - Abbvie/Stemcentrx; AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Ono Pharmaceutical (Inst)
 
Hajime Asahina
Speakers' Bureau - AstraZeneca Japan; Chugai Pharma; Lilly Japan
 
Morihito Okada
Speakers' Bureau - AstraZeneca; Chugai Pharma; Covidien; CSL Behring; Johnson & Johnson; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nihon Medi-Physics (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Takahiro Uchida
No Relationships to Disclose
 
Kana Watanabe
No Relationships to Disclose
 
Kosuke Hamai
No Relationships to Disclose
 
Taishi Harada
No Relationships to Disclose
 
Yukari Tsubata
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; MSD; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst)
 
Shunichi Sugawara
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Kunihiko Kobayashi
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
 
Kenji Sugio
No Relationships to Disclose
 
Satoshi Oizumi
Honoraria - AstraZeneca; Lilly
Research Funding - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai/Roche; Kissei Pharmaceutical; Merck Serono; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
 
Isamu Okamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)